Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of APF530 versus Aloxi for prevention of chemotherapy-induced nausea and vomiting
2007-005068-29Phase 3Completed
- Sponsor
- Heron Therapeutics, Inc.
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing APF530 arm with Aloxi arm (2 arms). Primary endpoint: Daily efficacy measures during days 1 to 5 after chemotherapy. Started Oct 2007; status: completed.
02
Drugs
granisetronpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2007-005068-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005068-29.